Alpine Immune Sciences has been granted a patent for variant CTLA-4 polypeptides and immunomodulatory proteins that can be used for treating autoimmune or inflammatory conditions. The patent also covers compositions and methods for producing and utilizing these proteins. The variant CTLA-4 polypeptide includes specific amino acid modifications and has a sequence that includes L63P and Y105L. GlobalData’s report on Alpine Immune Sciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Alpine Immune Sciences, Personalized cancer vaccines was a key innovation area identified from patents. Alpine Immune Sciences's grant share as of September 2023 was 19%. Grant share is based on the ratio of number of grants to total number of patents.
Variant ctla-4 polypeptide for treatment of autoimmune conditions
A recently granted patent (Publication Number: US11753458B2) describes a variant CTLA-4 polypeptide with specific amino acid modifications. The variant polypeptide includes an IgV domain or a specific binding fragment thereof, and the amino acid modifications are located at positions 29, 53, 56, 58, 82, 87, and 98. Additionally, the variant polypeptide contains L63P and Y105L amino acid modifications.
The patent claims that the variant CTLA-4 polypeptide specifically binds to the ectodomain of human ICOSL, human CD80, and/or human CD86 with increased affinity compared to the unmodified CTLA-4 polypeptide. The amino acid modifications responsible for this increased affinity include G29W, T53S, M56K, N58S, Q82R, M87V, and L98Q.
The variant CTLA-4 polypeptide can be a soluble protein that lacks the transmembrane and intracellular signaling domains, making it incapable of being expressed on the surface of a cell. It can also be linked to a multimerization domain.
The patent also describes a variant CTLA-4-Fc fusion protein, where the Fc domain is a variant Fc domain with reduced effector function. Additionally, an immunomodulatory polypeptide is disclosed, which consists of the variant CTLA-4 linked to a second polypeptide containing an immunoglobulin superfamily (IgSF) domain.
The patent covers various aspects related to the production and engineering of cells expressing the variant CTLA-4 polypeptide. It includes methods of introducing a nucleic acid molecule encoding the variant CTLA-4 polypeptide into a host cell to express the protein, as well as engineered cells expressing the variant CTLA-4 polypeptide.
Furthermore, the patent encompasses pharmaceutical compositions comprising the variant CTLA-4 polypeptide and a pharmaceutically acceptable excipient. These compositions can be used to modulate immune responses in subjects or for the treatment of diseases or conditions.
The patent also includes an article of manufacture, such as a vial or container, containing the pharmaceutical composition, as well as a kit comprising the composition and instructions for use.
In summary, the granted patent describes a variant CTLA-4 polypeptide with specific amino acid modifications that enhance its binding affinity to certain ectodomains. The patent covers various applications of the variant polypeptide, including fusion proteins, immunomodulatory polypeptides, engineered cells, pharmaceutical compositions, and methods of treatment and immune response modulation.
To know more about GlobalData’s detailed insights on Alpine Immune Sciences, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
